留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

结直肠癌肝转移立体定向消融放疗

李学敏 王皓 王俊杰

李学敏, 王皓, 王俊杰. 结直肠癌肝转移立体定向消融放疗[J]. 临床肝胆病杂志, 2021, 37(3): 522-526. DOI: 10.3969/j.issn.1001-5256.2021.03.006
引用本文: 李学敏, 王皓, 王俊杰. 结直肠癌肝转移立体定向消融放疗[J]. 临床肝胆病杂志, 2021, 37(3): 522-526. DOI: 10.3969/j.issn.1001-5256.2021.03.006
LI XM, WANG H, WANG JJ. Stereotactic ablative radiotherapy for colorectal cancer liver metastasis[J]. J Clin Hepatol, 2021, 37(3): 522-526. DOI: 10.3969/j.issn.1001-5256.2021.03.006
Citation: LI XM, WANG H, WANG JJ. Stereotactic ablative radiotherapy for colorectal cancer liver metastasis[J]. J Clin Hepatol, 2021, 37(3): 522-526. DOI: 10.3969/j.issn.1001-5256.2021.03.006

结直肠癌肝转移立体定向消融放疗

DOI: 10.3969/j.issn.1001-5256.2021.03.006
基金项目: 

科技部重大专项 2019YFB1311305

国家临床重点专科能力建设项目 胃肠道肿瘤综合诊治

详细信息
    作者简介:

    李学敏(1991—),女,医学博士,主要从事泌尿肿瘤、消化肿瘤的放射治疗

    通讯作者:

    王俊杰,junjiewang_edu@sina.cn

  • 利益冲突声明:所有作者均声明不存在利益冲突。
  • 作者贡献声明:李学敏负责调研整理文献,起草论文;王皓负责提出研究选题,修订论文;王俊杰负责终审论文,获取研究经费及指导性支持。
  • 中图分类号: R735.7; R735.3

Stereotactic ablative radiotherapy for colorectal cancer liver metastasis

  • 摘要: 全身治疗和转移灶局部治疗可以改善结直肠癌肝转移(CRLM)患者的生存。体部立体定向放射治疗,又称立体定向消融放疗(SABR),不仅是转移灶局部治疗的有效手段,还对全身免疫状态具有一定的影响。SABR可以直接杀伤肿瘤细胞,也通过对肿瘤细胞和非肿瘤细胞的影响改变肿瘤免疫微环境。SABR联合免疫治疗可能通过影响免疫应答的各个环节增加照射区域之外病灶远隔效应的发生率。立体定向近距离消融(SABT)是一种独立的微创治疗体系,具有疗程短、精确性高、疗效确切的特点。现就SABR和SABT在CRLM中的应用进行综述。
  • [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
    [2] SIEGEL RL, MILLER KD, GODING SAUER A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164. DOI: 10.3322/caac.21601
    [3] van der GEEST LG, LAM-BOER J, KOOPMAN M, et al. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases[J]. Clin Exp Metastasis, 2015, 32(5): 457-465. DOI: 10.1007/s10585-015-9719-0
    [4] van GESTEL YR, de HINGH IH, van HERK-SUKEL MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer[J]. Cancer Epidemiol, 2014, 38(4): 448-454. DOI: 10.1016/j.canep.2014.04.004
    [5] HOUSE MG, ITO H, GÖNEN M, et al. Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1, 600 patients during two decades at a single institution[J]. J Am Coll Surg, 2010, 210(5): 744-752, 752-755. DOI: 10.1016/j.jamcollsurg.2009.12.040
    [6] HELLMAN S, WEICHSELBAUM RR. Oligometastases[J]. J Clin Oncol, 1995, 13(1): 8-10. DOI: 10.1200/JCO.1995.13.1.8
    [7] CREASY JM, SADOT E, KOERKAMP BG, et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: What factors preclude cure?[J]. Surgery, 2018, 163(6): 1238-1244. DOI: 10.1016/j.surg.2018.01.004
    [8] GOLDBERG SN, GRASSI CJ, CARDELLA JF, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria[J]. J Vasc Interv Radiol, 2005, 16(6): 765-778. DOI: 10.1097/01.RVI.0000170858.46668.65
    [9] LOO BW Jr, CHANG JY, DAWSON LA, et al. Stereotactic ablative radiotherapy: What's in a name?[J]. Pract Radiat Oncol, 2011, 1(1): 38-39. DOI: 10.1016/j.prro.2010.07.001
    [10] GALLUZZI L, YAMAZAKI T, KROEMER G. Linking cellular stress responses to systemic homeostasis[J]. Nat Rev Mol Cell Biol, 2018, 19(11): 731-745. DOI: 10.1038/s41580-018-0068-0
    [11] SONG CW, LEE YJ, GRIFFIN RJ, et al. Indirect tumor cell death after high-dose hypofractionated irradiation: Implications for stereotactic body radiation therapy and stereotactic radiation surgery[J]. Int J Radiat Oncol Biol Phys, 2015, 93(1): 166-172. DOI: 10.1016/j.ijrobp.2015.05.016
    [12] PARK HJ, GRIFFIN RJ, HUI S, et al. Radiation-induced vascular damage in tumors: Implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)[J]. Radiat Res, 2012, 177(3): 311-327. DOI: 10.1667/RR2773.1
    [13] SONG CW, GLATSTEIN E, MARKS LB, et al. Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): Indirect cell death[J]. Int J Radiat Oncol Biol Phys, 2019.[Online ahead of print]
    [14] NIEMIERKO A, GOITEIN M. Implementation of a model for estimating tumor control probability for an inhomogeneously irradiated tumor[J]. Radiother Oncol, 1993, 29(2): 140-147. DOI: 10.1016/0167-8140(93)90239-5
    [15] BROWN JM, CARLSON DJ, BRENNER DJ. The tumor radiobiology of SRS and SBRT: Are more than the 5 Rs involved?[J]. Int J Radiat Oncol Biol Phys, 2014, 88(2): 254-262. DOI: 10.1016/j.ijrobp.2013.07.022
    [16] HOYER M, ROED H, TRABERG HANSEN A, et al. Phase Ⅱ study on stereotactic body radiotherapy of colorectal metastases[J]. Acta Oncol, 2006, 45(7): 823-830. DOI: 10.1080/02841860600904854
    [17] MÉNDEZ ROMERO A, WUNDERINK W, van OS RM, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors[J]. Int J Radiat Oncol Biol Phys, 2008, 70(5): 1447-1452. DOI: 10.1016/j.ijrobp.2007.08.058
    [18] LEE MT, KIM JJ, DINNIWELL R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases[J]. J Clin Oncol, 2009, 27(10): 1585-1591. DOI: 10.1200/JCO.2008.20.0600
    [19] RUSTHOVEN KE, KAVANAGH BD, CARDENES H, et al. Multi-institutional phase I/Ⅱ trial of stereotactic body radiation therapy for liver metastases[J]. J Clin Oncol, 2009, 27(10): 1572-1578. DOI: 10.1200/JCO.2008.19.6329
    [20] SCORSETTI M, COMITO T, TOZZI A, et al. Final results of a phase Ⅱ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer[J]. J Cancer Res Clin Oncol, 2015, 141(3): 543-553. DOI: 10.1007/s00432-014-1833-x
    [21] CHANG DT, SWAMINATH A, KOZAK M, et al. Stereotactic body radiotherapy for colorectal liver metastases: A pooled analysis[J]. Cancer, 2011, 117(17): 4060-4069. DOI: 10.1002/cncr.25997
    [22] JOO JH, PARK JH, KIM JC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(4): 876-883. DOI: 10.1016/j.ijrobp.2017.07.030
    [23] FRANZESE C, COMITO T, TOSKA E, et al. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy[J]. Radiother Oncol, 2019, 133: 220-226. DOI: 10.1016/j.radonc.2018.10.024
    [24] KANG JK, KIM MS, KIM JH, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT[J]. Clin Exp Metastasis, 2010, 27(4): 273-278. DOI: 10.1007/s10585-010-9325-0
    [25] CLERICI E, COMITO T, FRANZESE C, et al. Role of stereotactic body radiation therapy in the treatment of liver metastases: Clinical results and prognostic factors[J]. Strahlenther Onkol, 2020, 196(4): 325-333. DOI: 10.1007/s00066-019-01524-8
    [26] RULE W, TIMMERMAN R, TONG L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases[J]. Ann Surg Oncol, 2011, 18(4): 1081-1087. DOI: 10.1245/s10434-010-1405-5
    [27] JOO JH, PARK JH, KIM JC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(4): 876-883. DOI: 10.1016/j.ijrobp.2017.07.030
    [28] CHUA TC, SAXENA A, LIAUW W, et al. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases[J]. Ann Surg Oncol, 2010, 17(2): 492-501. DOI: 10.1245/s10434-009-0781-1
    [29] NORDLINGER B, SORBYE H, GLIMELIUS B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2013, 14(12): 1208-1215. DOI: 10.1016/S1470-2045(13)70447-9
    [30] DEMARIA S, NG B, DEVITT ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated[J]. Int J Radiat Oncol Biol Phys, 2004, 58(3): 862-870. DOI: 10.1016/j.ijrobp.2003.09.012
    [31] GOLDEN EB, CHHABRA A, CHACHOUA A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial[J]. Lancet Oncol, 2015, 16(7): 795-803. DOI: 10.1016/S1470-2045(15)00054-6
    [32] ABUODEH Y, VENKAT P, KIM S. Systematic review of case reports on the abscopal effect[J]. Curr Probl Cancer, 2016, 40(1): 25-37. DOI: 10.1016/j.currproblcancer.2015.10.001
    [33] NGWA W, IRABOR OC, SCHOENFELD JD, et al. Using immunotherapy to boost the abscopal effect[J]. Nat Rev Cancer, 2018, 18(5): 313-322. DOI: 10.1038/nrc.2018.6
    [34] DAGOGLU N, KARAMAN S, CAGLAR HB, et al. Abscopal effect of radiotherapy in the immunotherapy era: Systematic review of reported cases[J]. Cureus, 2019, 11(2): e4103. http://www.ncbi.nlm.nih.gov/pubmed/31057997
    [35] CHANG MC, CHEN YL, LIN HW, et al. Irradiation enhances abscopal anti-tumor effects of antigen-specific immunotherapy through regulating tumor microenvironment[J]. Mol Ther, 2018, 26(2): 404-419. DOI: 10.1016/j.ymthe.2017.11.011
    [36] VANPOUILLE-BOX C, DIAMOND JM, PILONES KA, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity[J]. Cancer Res, 2015, 75(11): 2232-2242. DOI: 10.1158/0008-5472.CAN-14-3511
    [37] RODRÍGUEZ-RUIZ ME, RODRÍGUEZ I, MAYORGA L, et al. TGFβ blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies[J]. Mol Cancer Ther, 2019, 18(3): 621-631. DOI: 10.1158/1535-7163.MCT-18-0558
    [38] RUDQVIST NP, PILONES KA, LHUILLIER C, et al. Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells[J]. Cancer Immunol Res, 2018, 6(2): 139-150. DOI: 10.1158/2326-6066.CIR-17-0134
    [39] DEWAN MZ, GALLOWAY AE, KAWASHIMA N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J]. Clin Cancer Res, 2009, 15(17): 5379-5388. DOI: 10.1158/1078-0432.CCR-09-0265
    [40] XING D, SIVA S, HANNA GG. The abscopal effect of stereotactic radiotherapy and immunotherapy: Fool's gold or El dorado?[J]. Clin Oncol (R Coll Radiol), 2019, 31(7): 432-443. DOI: 10.1016/j.clon.2019.04.006
    [41] CHI MS, MEHTA MP, YANG KL, et al. Putative abscopal effect in three patients treated by combined radiotherapy and modulated electrohyperthermia[J]. Front Oncol, 2020, 10: 254. DOI: 10.3389/fonc.2020.00254
    [42] WANG J, CHAI S, ZHENG G, et al. Expert consensus statement on computed tomography-guided 125I radioactive seeds permanent interstitial brachytherapy[J]. J Cancer Res Ther, 2018, 14(1): 12-17. DOI: 10.4103/jcrt.JCRT_888_17
    [43] WANG J, CHAI S, WANG R, et al. Expert consensus on computed tomography-assisted three-dimensional-printed coplanar template guidance for interstitial permanent radioactive 125I seed implantation therapy[J]. J Cancer Res Ther, 2019, 15(7): 1430-1434. DOI: 10.4103/jcrt.JCRT_434_19
    [44] WANG J, ZHANG F, GUO J, et al. Expert consensus workshop report: Guideline for three-dimensional printing template-assisted computed tomography-guided (125)I seeds interstitial implantation brachytherapy[J]. J Cancer Res Ther, 2017, 13(4): 607-612. DOI: 10.4103/jcrt.JCRT_412_17
    [45] WANG JJ. The concept of stereotactic ablation brachytherapy and practice[J]. Chin J Radiol Med Prot, 2020, 40(3): 173-177. (in Chinese) http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhfsyxyfhzz98202003009

    王俊杰. 立体定向近距离消融治疗概念的提出与实践[J]. 中华放射医学与防护杂志, 2020, 40(3): 173-177. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhfsyxyfhzz98202003009
    [46] MARTINEZ-MONGE R, NAG S, NIERODA CA, et al. Iodine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastatic to the liver[J]. Cancer, 1999, 85(6): 1218-1225. DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1218::AID-CNCR2>3.0.CO;2-F
    [47] NAG S, DEHAAN M, SCRUGGS G, et al. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2006, 64(3): 736-744. DOI: 10.1016/j.ijrobp.2005.08.029
  • 加载中
计量
  • 文章访问数:  37
  • HTML全文浏览量:  21
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-24
  • 修回日期:  2021-01-25
  • 刊出日期:  2021-03-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回